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Abstract
Objectives To characterise the risk of admission to hospital for
hyperkalaemia in elderly patients treated with
trimethoprim-sulfamethoxazole in combination with spironolactone.
Design Population based nested case-control study.
Setting Ontario, Canada, from 1 April 1992 to 1 March 2010.
Participants Cases were residents of Ontario aged 66 years or above
receiving chronic treatment with spironolactone and admitted to hospital
with hyperkalaemia within 14 days of receiving a prescription for either
trimethoprim-sulfamethoxazole, amoxicillin, norfloxacin, or nitrofurantoin.
Up to four controls for each case were identified from the same cohort,
matched on age, sex, and presence or absence of chronic kidney disease
and diabetes, and required to have received one of the study antibiotics
within 14 days before the case’s index date.
Main outcome measures Odds ratio for association between admission
to hospital with hyperkalaemia and receipt of a study antibiotic in the
preceding 14 days, adjusted for conditions and drugs that may influence
risk of hyperkalaemia.
Results During the 18 year study period, 6903 admissions for
hyperkalaemia were identified, 306 of which occurred within 14 days of
antibiotic use. Of these, 248 (81%) cases were matched to 783 controls.
10.8% (17 859/165 754) of spironolactone users received at least one
prescription for trimethoprim-sulfamethoxazole. Compared with
amoxicillin, prescription of trimethoprim-sulfamethoxazole was associated
with a marked increase in the risk of admission to hospital for
hyperkalaemia (adjusted odds ratio 12.4, 95% confidence interval 7.1
to 21.6). The population attributable fraction was 59.7%, suggesting that
approximately 60% of all cases of hyperkalaemia in older patients taking
spironolactone and treated with an antibiotic for a urinary tract infection
could be avoided if trimethoprim-sulfamethoxazole was not prescribed.
Treatment with nitrofurantoin was also associated with an increase in
the risk of hyperkalaemia (adjusted odds ratio 2.4, 1.3 to 4.6), but no
such risk was found with norfloxacin (adjusted odds ratio 1.6, 0.8 to 3.4)
Conclusions Among older patients receiving spironolactone, treatment
with trimethoprim-sulfamethoxazole was associated with a major increase
in the risk of admission to hospital for hyperkalaemia. This drug
combination should be avoided when possible.
Introduction
Spironolactone is a non-selective mineralocorticoid receptor
antagonist used to treat systolic heart failure, resistant
hypertension,ascites,andhyperaldosteronism.
1-3Theprescribing
of spironolactone increased considerably after the publication
of the Randomized Aldactone Evaluation Study (RALES),
which showed that the drug could reduce morbidity and
mortality in patients with severe left ventricular dysfunction.
4-6
Although spironolactone was generally well tolerated in that
study, serious hyperkalaemia is an important consideration for
patients receiving the drug in clinical practice. Subsequent
research has shown that hyperkalaemia occurs in up to a third
of patients receiving spironolactone, emphasising the need for
regular monitoring of electrolytes and the avoidance of other
drugs that can cause hyperkalaemia.
7-9
Theantibiotictrimethoprimhasstructuralandpharmacological
similarities to the potassium sparing diuretic amiloride and
reducesurinarypotassiumexcretionbyapproximately40%.
10 11
The inhibition of potassium secretion results in a dose related
antikaliuretic effect that may predispose susceptible people to
clinically important hyperkalaemia.
12 In combination with
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Research
RESEARCHsulfamethoxazole, trimethoprim is commonly used for the
treatment of urinary tract infections. Because
trimethoprim-sulfamethoxazole and spironolactone are both
widely used drugs, the likelihood of co-prescription is high.
However, the risk of hyperkalaemia associated with the
combineduseofthesedrugshasnotbeensystematicallystudied,
andevidencesupportingaclinicallymeaningfuldruginteraction
islimitedtocasereports.
13 14Wethereforesoughttocharacterise
the significance of this drug interaction in clinical practice.
Methods
Wedidapopulationbased,nestedcase-controlstudyofOntario
residents aged 66 years or older treated with spironolactone
between 1 April 1992 and 1 March 2010. We determined
prescription drug use by using the Ontario Drug Benefit
Database, which identifies prescriptions dispensed to Ontario
residents aged 65 years or older. Hospital admission data came
fromtheCanadianInstituteforHealthInformation’sDischarge
Abstract Database and demographic information from the
RegisteredPersonsDatabase.TheDischargeAbstractDatabase
containsclinicalinformationonalladmissions,discharges,and
samedaysurgeriesfromallhospitalsinOntario.Trainedhealth
information professionals abstract patients’ charts by using
standard diagnosis and procedure codes. We used the Ontario
HealthInsurancePlandatabasetoidentifyclaimsforphysicians’
services and the Ontario Diabetes Database for information on
diagnoses of diabetes.
15 These databases were linked in an
anonymous fashion by using encrypted health card numbers
and are regularly used to study drug safety, including the
consequences of drug interactions.
5 16-18
For each patient, we identified a period of continuous use of
spironolactone beginning with the first prescription for
spironolactone after the patient’s 66th birthday. We excluded
the first year of eligibility for coverage of prescription drugs
(age 65) to avoid incomplete drug records. Observation ended
with the first occurrence of a hospital admission for
hyperkalaemia, death, the end of the study period (31 March
2010), or cessation of spironolactone treatment, defined as a
lapseofmorethan180daysbetweenprescriptions.Intheevent
of such a lapse, we extended the observation period 180 days
from the date of the last prescription to identify outcomes that
may have precipitated cessation of treatment.
Within the cohort of continuous users of spironolactone, we
defined cases as those admitted to hospital with a diagnosis of
hyperkalaemia (international classifications of diseases, 9th
edition, code 276.7, and 10th edition, code E87.5) within 14
daysofreceivingaprescriptionforoneoffourstudyantibiotics:
trimethoprim-sulfamethoxazole,norfloxacin,nitrofurantoin,or
amoxicillin. We did not include prescriptions for trimethoprim
monotherapy,becausethedrugisinvariablyusedincombination
with sulfamethoxazole in Canada. We included only patients
who had hyperkalaemia at the time of admission, rather than
those who developed hyperkalaemia during the course of a
hospital admission. We restricted our analyses to antibiotics
that are primarily used to treat urinary tract infections to avoid
the potential confounding effects of other systemic infections.
The date of hospital admission served as the index date for all
analyses, and we considered only the first instance of hospital
admission for hyperkalaemia for patients with more than one
such admission during the study period. We excluded patients
if they received prescriptions for multiple antibiotics or any
non-study antibiotics in the 30 days before the index date.
Fromwithinthecohortofpatientsreceivingspironolactone,we
selected up to four controls for each case by using incidence
densitysampling.
19Werequiredcontrolstohavehadnohospital
admission for hyperkalaemia before the index date and to have
received one of the study antibiotics within 14 days before the
index date. Consequently, all cases and controls were older
patients receiving spironolactone who had also received
treatmentwithoneofthestudyantibiotics.Wematchedcontrols
andcasesonageattheindexdate(plusorminusoneyear),sex,
presenceorabsenceofdiabetes(basedonreviewofthevalidated
OntarioDiabetesDatabase
15),andpresenceorabsenceofchronic
kidney disease, determined from physicians’ claims, hospital
admission records, and receipt of dialysis in the year before the
index date. Each patient could serve only once as a control.
When fewer than four control patients were available for each
case, we analysed only those controls and maintained the
matching process. We excluded any cases that could not be
matched to at least one control.
Statistical analysis
We calculated descriptive statistics for baseline demographic
and clinical characteristics of cases and controls, as well as
standardised differences to test for differences between the two
groups.Standardiseddifferencesoflessthan0.1indicateagood
balance between the cases and controls for a given covariate.
20
We used conditional logistic regression to estimate the odds
ratio and 95% confidence intervals for the association between
hyperkalaemia related hospital admission and receipt of a
prescriptionfortrimethoprim-sulfamethoxazoleinthepreceding
14 days, using amoxicillin treated patients as the reference
group. We selected amoxicillin as the reference antibiotic
because, with rare exceptions, it should not cause
hyperkalaemia.
21 To test the specificity of our findings, we also
examined the association between hyperkalaemia and
prescription of nitrofurantoin or norfloxacin, antibiotics
commonly used to treat community acquired urinary tract
infections. We hypothesised that these drugs would not be
associated with an increased risk of hyperkalaemia relative to
amoxicillin. We used multivariable conditional logistic
regression to adjust for medical conditions and classes of
prescriptiondrugsthatmayinfluencetheriskofhyperkalaemia
(see web appendix).
22-25 To ascertain whether a dose-response
relation existed between trimethoprim and hyperkalaemia, we
repeated our primary analysis, stratifying exposure to
trimethoprim-sulfamethoxazole according to prescription for
singlestrength(400mg/80mg)ordoublestrength(800mg/160
mg) tablets. Finally, we determined the population attributable
fraction, defined in this study as the fraction of all cases
(exposed and unexposed) that would not have occurred if
exposure to trimethoprim-sulfamethoxazole had been
avoided.
26 27 We used SAS version 9.2 for all analyses.
Results
We identified 165 754 patients treated with spironolactone
during the 18 year study period, of which 17 859 (10.8%)
received at least one prescription for
trimethoprim-sulfamethoxazoleduringthestudyperiod.Within
the cohort of spironolactone users, we identified 6903
admissions for hyperkalaemia, 306 of which occurred within
14daysofreceivinganantibioticofinterest.Mostcases(n=248;
81%) were matched to at least one control. Cases and controls
were similar with respect to age, residence in a long term care
facility, and history of diabetes (table 1⇓). As expected,
comorbidities and drugs known to increase the risk of
hyperkalaemia were more prevalent among cases than among
controls.
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RESEARCHIn the primary analysis, trimethoprim-sulfamethoxazole was
associated with a marked increase in the risk of hospital
admission for hyperkalaemia among patients receiving
spironolactone (table 2⇓). After multivariable adjustment,
patients admitted to hospital with hyperkalaemia were more
than 12 times as likely to have received a recent prescription
for trimethoprim-sulfamethoxazole than for amoxicillin
(adjusted odds ratio 12.4, 95% confidence interval 7.1 to 21.6).
When we stratified the data by dose, we found a higher risk of
hospital admission for hyperkalaemia with the double strength
formulation of trimethoprim-sulfamethoxazole (adjusted odds
ratio13.5,7.5to24.2)thanwithsinglestrengthtablets(adjusted
odds ratio 9.7, 4.7 to 19.9). Treatment with nitrofurantoin was
also associated with an increased risk of hyperkalaemia during
spironolactone treatment (adjusted odds ratio 2.4, 1.3 to 4.6).
In contrast, we found no association between hyperkalaemia
and receipt of norfloxacin (adjusted odds ratio 1.6, 0.8 to 3.4).
Thepopulationattributablefractionwas59.7%,suggestingthat
approximately 60% of all cases of hyperkalaemia in older
patients taking spironolactone and treated with an antibiotic for
a urinary tract infection could be avoided if
trimethoprim-sulfamethoxazole was not prescribed.
Finally, because we did not attain a full match for all of our
cases, we did a sensitivity analysis matching cases and controls
only on sex, thereby matching all cases to at least one control.
Results of the sensitivity analysis were consistent with those
obtained with the originally matched cohort.
Discussion
Inthispopulationbasedstudyspanning18years,wefoundthat
theprescriptionoftrimethoprim-sulfamethoxazolewasstrongly
associatedwithadmissiontohospitalforhyperkalaemiaamong
elderly patients treated with spironolactone. Treatment with
nitrofurantoin was associated with a less pronounced increase
in the risk of hospital admission for hyperkalaemia, whereas
we found no such risk with norfloxacin. Our findings support
the existence of a clinically important and potentially life
threatening drug interaction between
trimethoprim-sulfamethoxazole and spironolactone at the
population level. This represents the first estimate of the risk
of co-prescribing these drugs in clinical practice.
We found a less striking increase in the risk of hyperkalaemia
with nitrofurantoin treatment. This may reflect a “channelling”
effect, in which patients at greater risk of hyperkalaemia were
more likely to have been prescribed nitrofurantoin rather than
trimethoprim-sulfamethoxazole,althoughthissamephenomenon
should also apply to norfloxacin. Some evidence indicates that
this association may reflect a causal relation. In vitro
experiments show that nitrofurantoin inhibits steroid
biosynthesis,resultingina50%reductioninaldosteronerelease
from adrenocortical cells.
28 An additional, previously
underappreciated drug interaction may thus exist between
nitrofurantoin and spironolactone that may predispose
susceptible patients to hyperkalaemia.
Our study has important clinical implications. In our cohort,
10.8% of patients received at least one prescription for
trimethoprim-sulfamethoxazole during the study period and
were therefore at increased risk of hyperkalaemia. Serious
hyperkalaemiacancausesuddendeathandisthemostdangerous
complication of treatment with spironolactone. Consequently,
strategies aimed at minimising the risk of hyperkalaemia are
essential. Our findings suggest that in patients receiving
spironolactone, avoidance of trimethoprim-sulfamethoxazole
is prudent when clinically appropriate.
Limitations
Some limitations of our work merit emphasis. We used
administrative data and had no access to serum potassium
concentrations, indices of renal function (including estimated
glomerular filtration rate), adherence to drug treatment, or use
of non-prescription drugs that may have influenced the risk of
hyperkalaemia. However, these limitations apply equally to all
antibiotics studied, and in particular would not be expected to
differappreciablybetweentrimethoprim-sulfamethoxazoleand
amoxicillin. We also could not identify hyperkalaemia in
outpatients and hyperkalaemia related mortality in the
pre-hospital setting. However, this would lead to
underestimation of the clinical consequences of this drug
interaction. Because some clinicians may appreciate the risk of
hyperkalaemiawithtrimethoprim-sulfamethoxazole,differential
outcome ascertainment is a possible source of bias. However,
this is unlikely to have affected our findings as electrolyte
concentrations are routinely measured in older patients
presenting to hospital. In addition, our findings may not apply
to younger patients with fewer risk factors for hyperkalaemia.
Furthermore, as with all observational studies, residual
confounding is a potential source of bias. However, given the
magnitude of the observed association, we find it difficult to
conceive of an unmeasured confounder that would be
differentiallydistributedamongthevariousantibioticsthatcould
beaccountingforourfindings.Finally,theaccuracyofhospital
discharge coding for hyperkalaemia has not been validated,
althoughthesamelimitationappliestopreviousresearchonthe
clinical consequences of drug interactions leading to
hyperkalaemia.
5 16
Conclusions
Prescription of trimethoprim-sulfamethoxazole to elderly
patientsreceivingtreatmentwithspironolactonewasassociated
with a major increase in the risk of hyperkalaemia, and this risk
greatly exceeded that observed with other commonly used
antibiotics for urinary tract infection. Increased awareness of
this drug interaction among pharmacists and physicians is
needed to ensure that the potential for life threatening
hyperkalaemia with this drug combination is minimised, either
by selection of alternative antibiotics when appropriate or by
close monitoring of patients treated with both drugs.
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RESEARCHWhat is already known on this topic
Drug interactions are an important and avoidable cause of hyperkalaemia
Trimethoprim (generally combined with sulfamethoxazole in North America) and spironolactone can both cause
hyperkalaemia, yet the risks associated with this combination are unknown
What this study adds
Compared with amoxicillin, prescription of trimethoprim-sulfamethoxazole was associated with a more than 12-fold
increase in the risk of hospital admission for hyperkalaemia among older patients taking spironolactone
10.8% of spironolactone users received at least one prescription for trimethoprim-sulfamethoxazole, thereby being
placed at excess risk of hyperkalaemia
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Table 1| Characteristics of cases and controls. Values are numbers (percentages) unless stated otherwise
Standardised difference* Controls (n=783) Cases (n=248) Characteristics
0.01 81 (75-87) 82 (75-87) Median (interquartile range) age (years):
0.02 203 (26) 66 (27) 66-74
0.04 370 (47) 112 (45) 75-84
0.03 210 (27) 70 (28) ≥85
0.11 551 (70) 162 (65) Female sex
0.66 3 (1-5) 1 (1-2) Median (interquartile range) years of spironolactone use
Charlson co-morbidity index:
0.29 214 (27) 37 (15) No hospital admission
0.22 94 (12) 13 (5) 0
0.01 131 (17) 41 (17) 1
0.39 344 (44) 157 (63) ≥2
0.35 282 (36) 132 (53) History of congestive heart failure (3 years)
0.19 44 (6) 26 (10) History of chronic liver disease (1 year)
0.18 17 (2) 13 (5) History of chronic kidney disease (1 year)
0.04 356 (45) 118 (48) Diabetes
0.05 168 (21) 48 (19) Residence in a long term care facility
0.34 16 (12-20) 17 (14-22) Median (interquartile range) No of prescription drugs in
previous year
Drug use in preceding 120 days:
0.21 561 (72) 201 (81) Non-potassium sparing diuretics
0.09 15 (2) 8 (3) Potassium sparing diuretics†
0.12 303 (39) 111 (45) β adrenergic receptor blockers
0.06 20 (3) 9 (4) Potassium supplements
0.23 202 (26) 90 (36) Non-steroidal anti-inflammatory drugs
0.49 420 (54) 191 (77) Renin-angiotensin-aldosterone inhibitors
Fifth of income:
0.05 171 (22) 49 (20) 1 (lowest)
0.11 167 (21) 64 (26) 2
0.09 140 (18) 53 (21) 3
0.1 159 (20) 41 (17) 4
0.07 140 (18) 38 (15) 5 (highest)
0.05 6 (1) ≤5 Missing
*Difference between cases and controls divided by standard deviation; standardised differences <0.1 indicate good balance between cases and controls.
†Amiloride and combination products; triamterene and combination products.
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RESEARCHTable 2| Association between hospital admission involving hyperkalaemia and recent antibiotic use
Adjusted odds ratio* (95% CI) Odds ratio (95% CI) No (%) controls (n=783) No (%) cases (n=248)
Use of antibiotic in preceding
14 days
12.4 (7.1 to 21.6) 11.0 (6.8 to 17.8) 162 (21) 161 (65) TMP-SMX
2.4 (1.3 to 4.6) 2.5 (1.4 to 4.4) 159 (20) 34 (14) Nitrofurantoin
1.6 (0.8 to 3.4) 1.5 (0.8 to 2.9) 137 (17) 17 (7) Norfloxacin
1.0 (reference) 1.0 (reference) 325 (42) 36 (15) Amoxicillin
TMP/SMX=trimethoprim-sulfamethoxazole.
*Adjusted for age category, congestive heart failure, chronic liver disease, chronic kidney disease, Charlson co-morbidity index, fifth of income, living in long term
care facility, number of prescription drugs in previous year, number of years of spironolactone treatment, and drugs (β adrenergic receptor blockers, potassium
sparing diuretics, non-potassium sparing diuretics, non-steroidal anti-inflammatory drugs, potassium supplements, renin-angiotensin-aldosterone inhibitors).
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